Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
about
Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studiesNitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritisPain management for rheumatoid arthritis and cardiovascular or renal comorbidityCardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysisA turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicityNSAIDs and Cardiovascular Diseases: Role of Reactive Oxygen SpeciesCyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular riskNSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studiesCausal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis.Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trialsGI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trialSafe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risksThe impact of NSAID treatment on cardiovascular risk - insight from Danish observational data.EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients.Myeloid cell microsomal prostaglandin E synthase-1 fosters atherogenesis in mice.Update on the use of topical NSAIDs for the treatment of soft tissue and musculoskeletal pain: a review of recent data and current treatment options.A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo.Etoricoxib--preemptive and postoperative analgesia (EPPA) in patients with laparotomy or thoracotomy--design and protocolsEffects of diclofenac and celecoxib on osteoclastogenesis during alveolar bone healing, in vivo.Cyclooxygenase-1-selective inhibitors based on the (E)-2'-des-methyl-sulindac sulfide scaffold.A cohort study to evaluate cardiovascular risk of selective and nonselective cyclooxygenase inhibitors (COX-Is) in arthritic patients attending orthopedic department of a tertiary care hospitalPhysiology. COX-2 inhibitors and cardiovascular risk.Topical nonsteroidal anti-inflammatory drugs for the treatment of pain due to soft tissue injury: diclofenac epolamine topical patch.Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysisSafety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease.Relative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: implications for clinical practice.Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries.Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs.How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.Common secondary causes of resistant hypertension and rational for treatmentAssessment of rescue opioid use in patients with post-bunionectomy pain treated with diclofenac potassium liquid-filled capsules.Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway.The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors in the treatment of osteoarthritis in Saudi ArabiaEffects of cyclooxygenase inhibition on cardiovascular function in a hypercholesterolemic swine model of chronic ischemia.Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials.Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative.A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis.Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard cCost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities.
P2860
Q21144617-5A8B956F-1F8F-4141-B1C0-DFB1D050E37FQ21195404-9C7AF60A-147F-4255-A58A-CBF8102ED799Q24235971-7B24A60E-69AF-44B7-A7D8-0F0D6BA29271Q24601392-781A678A-D84E-43A1-8F54-2CFE5EE9C864Q24615651-5D65A8D0-6C51-4B81-A8B0-BA660CAE8B37Q26784322-AB3526C1-DD50-4C75-B26A-AE9AD587469CQ28219220-A2CCCE50-E1B0-416B-B95D-6C9229D91017Q28742977-8016DF48-DF76-4FE2-B47F-C41ADDF12D5BQ30411394-B0EF7E55-00BD-4A12-B227-B4734CACD00BQ30430170-2797A76C-3028-4921-977C-9F587F2D86A3Q30537237-4B042839-8B74-4E13-A957-5425F4E905C8Q30629677-5090FF29-63E0-4682-A4D5-9F9BE2A51619Q30791071-D75296EC-A71E-4570-91F5-04798C123CB0Q33292103-35E038B2-CEF3-47DE-9D09-5DC21FB0AF21Q33367787-519B41AE-65FC-463E-9F2A-78678526884EQ33607097-A5C6D98B-C57C-405C-B2A5-0AA8FC2DBA09Q33632966-E5784811-3697-403D-9C64-2C2F564AD926Q33633625-86159635-BF64-42BF-8D94-0EC45889E6B3Q33934086-4A1A35E7-EE49-492B-BA4B-5721D42E50E5Q33991545-D479CDCA-2E1F-454C-8F54-5164090E9ACAQ34134282-55C343C2-F19C-4DA3-AAF1-0A9E8EEAE276Q34259503-40ABF58B-528D-42DD-A0A5-8FC6B84D4909Q34281737-C16087E9-B1BE-446F-98B8-98C915068E5FQ34418290-1D02615C-4EA2-42C7-841E-4434971B3DB1Q34471991-83925047-20E5-4B89-9BBA-B17E4DD9AA5AQ34474985-58002013-116A-4A5D-A7AB-0FFA85A86790Q34556831-40252F9D-0566-4FFD-AD2E-4AC8F1CB257FQ34592490-E4E8D832-4728-4099-9670-00B6E717EDA3Q34601141-D525E44F-C931-46EA-BC21-53645228E296Q34603723-573681B0-C4CB-4F46-98A3-A38DCFD83E07Q34669789-C729D1AC-6EE8-4123-AE91-1EF7B60B64F9Q35067593-DCBA65D4-F7B2-460A-B2EA-897162A882B0Q35098611-098ECEF6-B602-47B9-85DC-2BAE3A6BE7CCQ35743672-0EE81E8A-32FB-459C-B41B-C3F1EDDC7322Q35921247-82498C10-DDA2-44DE-A9E4-D1CAB12F82BAQ36013803-579DC99B-6681-4BED-AA2E-591163CFCCEBQ36096803-ECB69291-FD6D-4616-973E-62C6827309BEQ36163165-EBF27AE7-0C20-4FAD-80A5-F253F91D633CQ36584086-65FC48EE-0B83-4FE2-B006-304A67B4CA20Q36600338-2D44B1B6-3D9D-4A5C-AF4C-9557637897CC
P2860
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Cardiovascular outcomes with e ...... amme: a randomised comparison.
@ast
Cardiovascular outcomes with e ...... amme: a randomised comparison.
@en
Cardiovascular outcomes with e ...... Diclofenac Arthritis Long-term
@nl
type
label
Cardiovascular outcomes with e ...... amme: a randomised comparison.
@ast
Cardiovascular outcomes with e ...... amme: a randomised comparison.
@en
Cardiovascular outcomes with e ...... Diclofenac Arthritis Long-term
@nl
prefLabel
Cardiovascular outcomes with e ...... amme: a randomised comparison.
@ast
Cardiovascular outcomes with e ...... amme: a randomised comparison.
@en
Cardiovascular outcomes with e ...... Diclofenac Arthritis Long-term
@nl
P2093
P921
P1433
P1476
Cardiovascular outcomes with e ...... amme: a randomised comparison.
@en
P2093
Alise S Reicin
Amarjot Kaur
Christopher P Cannon
Claire Bombardier
Erland Erdmann
Garret A FitzGerald
James A Bolognese
Loren Laine
MEDAL Steering Committee
Michael E Weinblatt
P304
P356
10.1016/S0140-6736(06)69666-9
P407
P577
2006-11-01T00:00:00Z